CD4 and HIV infectious disease: While there are certainly drawbacks to this model, such as GVHD and the inability to replace CD4 T cells once they are depleted by HIV infection, this model has been successfully used in preclinical, FDA mandated biotoxicity and efficacy studies [54, 58] and has mirrored the outcome of several clinical trials exploring gene therapy approaches to treat HIV infection [53, 54].